David Floyd, Ph.D.

Dr. Floyd has over 20 years of clinical research experience.

Most recently he was the Executive Vice President and Chief Scientific Officer of Pharmacopeia, Inc., a US based corporation that was later acquired by Ligand.

He consulted extensively and was a member of several scientific advisory boards including ARYx, Redpoint Pharmaceuticals, Kalypsys, Medicines for Malaria Venture (MMV), Gentara, ExSAR, Millenium, and others

Previously Dr. Floyd worked at Bristol-Myers Squibb (BMS), first as a Research Investigator in the Department of Organic Chemistry, and through the years progressed through several roles of increasing responsibility. He spent more than 10 years as Vice President, Discovery Chemistry, at the BMS Pharmaceutical Research Institute.

Dr. Floyd started his pharmaceutical career as a Junior Chemist in Organic Chemistry at Alza Corporation in Palo Alto, California and subsequently earned a Ph.D. in Organic Chemistry from the University of Michigan followed by 2 years as an NIH Postdoctoral Fellow at Harvard University with Professor E. J. Corey.